

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/954,975	09/18/2001	Jack Stapleton	IOWA:033US/SLH	7706

7590 11/05/2002
FULBRIGHT & JAWORSKI L.L.P.
SUITE 2400
600 CONGRESS AVENUE
AUSTIN, TX 78701

EXAMINER

CHOI, FRANK I

ART UNIT	PAPER NUMBER
----------	--------------

1616

DATE MAILED: 11/05/2002

8

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/954,975

Applicant(s)

STAPLETON ET AL.

Examiner

Frank I Choi

Art Unit

1616

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-40 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). ____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3. 6) ☒ Other: *Appendix B*.

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-4, 7-13, 16-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Murrer et al. (US Pat. 5,093,134) in view of the acknowledged prior art and Narashimhan et al.

Murrer et al. teaches a composition containing gallium which is less toxic than AZT and HPA-23 which is effective against HIV-1 and HIV-2 (Columns 3,4, Table, Column 4, lines 60-64). It is taught that the active compounds may be administered by injection, or in a capsule or tablet (Column 5, lines 10-20). It is taught the compositions provide active compound in the dosage range in humans of from 0.1 to 100 mg/kg body weight per day, in a single dose or a number of smaller doses and that other active compounds may be used in the compositions or administered separately (Column 6, lines 3-14).

Applicant acknowledges that it is known that HIV results in rejection of T-lymphocytes because the same when infected with HIV are removed by host immune response and that the reduction of T-lymphocytes can lead to the development of AIDS (Pg. 2, lines 15-24). It is known that current treatments include treatment with dideoxynucleotides, such as AZT, dideoxyinosine and dideoxycytidine (Pg. 2, lines 27-29). It is known that inhibition of ribonucleotide reductase inhibits HIV replication and that ribonucleotide reductase inhibitors

potentiate the activity of dideoxynucleotides which are nucleoside reverse transcriptase inhibitors (Pg. 3, lines 8-20).

Narashimhan et al. teach that gallium inhibits ribonucleotide reductase (Abstract).

The difference between the prior art and the claimed invention is that the prior art does not expressly disclose a method of treating HIV in a human infected with the same with gallium and a composition or kit containing gallium and nucleoside inhibitor. However, the prior art amply suggests the same as it is known that compositions containing gallium are effective against HIV and are less toxic than AZT, that gallium is a ribonucleotide reductase inhibitor and that said ribnucleotide reductase inhibitors potentiate the effects of dideoxynucleotides. As such, it would have been well within the skill of and one of ordinary skill in the art would have been motivated to modify the prior art as above with the expectation that gallium containing compositions would be effective against HIV in humans and that the combination of gallium compositions with nucleoside inhibitors would result in more effective HIV therapy.

Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references.

Claims 1-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over the acknowledged prior art in view of Narashimhan et al., Collery et al. (US Pat. 5,525,598) and Bernstein (US Pat. 5,883,088).

Applicant acknowledges that it is known that HIV results in rejection of T-lymphocytes because the same when infected with HIV are removed by host immune response and that the reduction of T-lymphocytes can lead to the development of AIDS (Pg. 2, lines 15-24). It is

known that current treatments include treatment with dideoxynucleotides, such as AZT, dideoxyinosine and dideoxycytidine (Pg. 2, lines 27-29). It is known that inhibition of ribonucleotide reductase inhibits HIV replication and that ribonucleotide reductase inhibitors potentiate the activity of dideoxynucleotides which are nucleoside reverse transcriptase inhibitors (Pg. 3, lines 8-20).

Narashimhan et al. teach that gallium, for example gallium nitrate and gallium citrate, inhibit ribonucleotide reductase (Abstract).

Collery et al. teach that gallium complexes are effective in treating HIV and that gallium nitrate inhibits reverse transcriptase found in retroviruses, such as HIV (Column 1, lines 24-32, Columns 15,16, Table VII).

Bernstein teaches that gallium complexes of hydroxypyrones exhibit increased oral availability and are also suitable for administration intravenously (See entire document).

The difference between the prior art and the claimed invention is that the prior art does not expressly disclose a method of treating HIV in a human infected with the same with gallium and a composition or kit containing gallium and nucleoside inhibitor. However, the prior art amply suggests the same as it is known that compositions containing gallium are effective against HIV and are less toxic than AZT, that gallium is a ribonucleotide reductase inhibitor and that said ribnucleotide reductase inhibitors potentiate the effects of dideoxynucleotides. As such, it would have been well within the skill of and one of ordinary skill in the art would have been motivated to modify the prior art as above with the expectation that gallium containing compositions would be effective against HIV in humans and that the combination of gallium compositions with nucleoside inhibitors would result in more effective HIV therapy.

Art Unit: 1616

Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references.

Conclusion

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or (703) 305-3592.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (703) 308-0067. Examiner maintains a flexible schedule. However, Examiner may generally be reached Monday-Friday, 8:00 am – 5:30 pm (EST), except the first Friday of the each biweek which is Examiner's normally scheduled day off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. José Dees, can be reached on (703) 308-4628. Additionally, Technology Center 1600's Receptionist and Customer Service can be reached at (703) 308-1235 and (703) 308-0198, respectively.

FIC

November 2, 2002



JOHN PAK
PRIMARY EXAMINER
GROUP 1600



Appendix B

The following papers have not been made part of the permanent records of the United States Patent and Trademark Office (Office) for this application (37 CFR 1.52(a)) because of damage from the United States Postal Service irradiation process:

Mailroom Stamp Date

4/22/2002

Certificate of Mailing Date

4/14/2002

The above-identified papers, however, were not so damaged as to preclude the USPTO from making a legible copy of such papers. Therefore, the Office has made a copy of these papers, substituted them for the originals in the file, and stamped that copy:

COPY OF PAPERS ORIGINALLY FILED

If applicant wants to review the accuracy of the Office's copy of such papers, applicant may either inspect the application (37 CFR 1.14(d)) or may request a copy of the Office's records of such papers (*i.e.*, a copy of the copy made by the Office) from the Office of Public Records for the fee specified in 37 CFR 1.19(b)(4). Please do **not** call the Technology Center's Customer Service Center to inquiry about the completeness or accuracy of Office's copy of the above-identified papers, as the Technology Center's Customer Service Center will **not** be able to provide this service.

If applicant does not consider the Office's copy of such papers to be accurate, applicant must provide a copy of the above-identified papers (except for any U.S. or foreign patent documents submitted with the above-identified papers) with a statement that such copy is a complete and accurate copy of the originally submitted documents. If applicant provides such a copy of the above-identified papers and statement within **THREE MONTHS** of the mail date of this Office action, the Office will add the original mailroom date and use the copy provided by applicant as the permanent Office record of the above-identified papers in place of the copy made by the Office. Otherwise, the Office's copy will be used as the permanent Office record of the above-identified papers (*i.e.*, the Office will use the copy of the above-identified papers made by the Office for examination and all other purposes). This three-month period is not extendable.